Horizon Technology Finance Corp (HRZN) - Q1 2021 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2021. Horizon Technology Finance Corp is an externally managed, closed-end, non-diversified business development company (BDC) and regulated investment company (RIC). The Company primarily makes secured debt investments in development-stage companies within the technology, life science, healthcare information and services, and sustainability sectors.
Key Financial Metrics
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Total Investment Income | $13.2 million | $10.1 million |
| Net Investment Income | $6.0 million | $4.3 million |
| Net Increase in Net Assets from Operations | $6.0 million | $(0.7) million |
| Net Asset Value (NAV) per Share | $11.07 | $11.48 |
| Total Assets | $469.6 million | $407.2 million |
| Total Borrowings (Net) | $242.1 million | $185.8 million |
| Cash and Cash Equivalents | $82.1 million | $40.0 million |
| Portfolio Turnover Ratio | 5.6% | 17.3% |
Material Changes vs. Prior Period
- Investment Income Growth: Total investment income increased 30.7% to $13.2 million, driven by a 19.0% increase in the average size of the debt investment portfolio and $1.3 million in interest income received from a portfolio company previously on non-accrual status.
- Expense Increases: Total expenses rose 22.6% to $7.2 million. Interest expense increased 25.6% due to higher average borrowings. The performance-based incentive fee increased 40.1% to $1.5 million due to higher Pre-Incentive Fee Net Investment Income.
- Realized and Unrealized Gains/Losses: The Company reported a net realized loss of $5.2 million, primarily due to the settlement of one debt investment. This was offset by net unrealized appreciation of $5.2 million, resulting in a net increase in net assets from operations of $6.0 million, compared to a decrease of $0.7 million in Q1 2020.
- Debt Issuance: In March 2021, the Company issued $57.5 million of 4.875% Notes due 2026. Concurrently, it announced the redemption of its $37.4 million 2022 Notes.
Guidance, Outlook, and Risks
- Capital Deployment: The Company utilized cash and available borrowings to fund new investments, including a $2.5 million debt investment to F-Star Therapeutics, Inc. in April 2021.
- Liquidity: As of March 31, 2021, the Company held $82.1 million in cash and cash equivalents. It has $125.0 million in total commitment capacity under the Key Facility (fully available) and $49.2 million under the NYL Facility.
- Dividends: The Board declared monthly distributions of $0.10 per share for June, July, and August 2021. For Q1 2021, distributions declared were $0.30 per share, fully covered by net investment income of $0.31 per share.
- Risks: The filing highlights risks associated with the COVID-19 pandemic, interest rate volatility (100% of debt portfolio is floating rate), and the potential for portfolio companies to require additional capital. The Company maintains an asset coverage ratio of 189%, well above the 150% regulatory minimum.
Investor Verification Checklist
- Debt Redemption: Verify the execution of the $37.4 million 2022 Notes redemption scheduled for April 24, 2021, and the associated acceleration of unamortized debt issuance costs ($0.4 million).
- Portfolio Quality: Review the internal credit rating distribution; as of March 31, 2021, 78.5% of the debt portfolio was rated "3" (standard risk) and 19.9% was rated "4" (highest quality), with no "1" rated assets.
- Unfunded Commitments: Note the $89.0 million in unfunded commitments to extend credit to portfolio companies, which represents a significant off-balance-sheet obligation.
- Valuation Methodology: Confirm that 99.3% of the portfolio ($377.3 million) is classified as Level 3 fair value, relying on unobservable inputs and management judgment.